Epstein-Barr virus DNAemia is an early surrogate marker of the net state of immunosuppresion in solid organ transplant recipients
BACKGROUND: Epstein-Barr virus (EBV) DNAemia (EBVd) may be a surrogate marker of the net state of immunosuppression after solid organ transplantation (SOT).
METHODS: A sample of 81 SOT recipients (53 renal, 21 liver, and 7 cardiac) from our institution (2003-2004) surviving more than 180 days was analyzed. EBVd was monitored in whole blood within the first 6 months using a real-time polymerase chain reaction assay. Using a Cox proportional hazards model, duration and magnitude of EBVd were assessed as potential surrogate markers for the occurrence of late adverse events (>6 months): graft dysfunction, graft loss, death, and immunosuppression-related adverse events (IRAE), defined by the occurrence of solid organ tumor and opportunistic and severe infections.
RESULTS: A median of 10 blood samples per patient was screened. A total of 68 (84%) patients had detectable EBVd. Persistent EBVd (>30 days) was found in 40 (49.4%) and high EBVd (>1500 copies/mL) in 35 (43.3%). Multivariate analyses showed that persistent EVBd and high EBVd levels were independently related to the development of IRAE (hazard ratio, 2.95 and 4.32, respectively), whereas no significant associations were observed with late graft dysfunction or graft loss.
CONCLUSIONS: Persistent and high levels of EBVd within the first 6 months after SOT are surrogate markers of increased risk of IRAE.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2013 |
---|---|
Erschienen: |
2013 |
Enthalten in: |
Zur Gesamtaufnahme - volume:95 |
---|---|
Enthalten in: |
Transplantation - 95(2013), 5 vom: 15. März, Seite 688-93 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
San-Juan, Rafael [VerfasserIn] |
---|
Links: |
---|
Themen: |
Biomarkers |
---|
Anmerkungen: |
Date Completed 09.05.2013 Date Revised 17.03.2022 published: Print Citation Status MEDLINE |
---|
doi: |
10.1097/TP.0b013e31827a4bd6 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM223775754 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM223775754 | ||
003 | DE-627 | ||
005 | 20231224061451.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231224s2013 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1097/TP.0b013e31827a4bd6 |2 doi | |
028 | 5 | 2 | |a pubmed24n0746.xml |
035 | |a (DE-627)NLM223775754 | ||
035 | |a (NLM)23274972 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a San-Juan, Rafael |e verfasserin |4 aut | |
245 | 1 | 0 | |a Epstein-Barr virus DNAemia is an early surrogate marker of the net state of immunosuppresion in solid organ transplant recipients |
264 | 1 | |c 2013 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 09.05.2013 | ||
500 | |a Date Revised 17.03.2022 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a BACKGROUND: Epstein-Barr virus (EBV) DNAemia (EBVd) may be a surrogate marker of the net state of immunosuppression after solid organ transplantation (SOT) | ||
520 | |a METHODS: A sample of 81 SOT recipients (53 renal, 21 liver, and 7 cardiac) from our institution (2003-2004) surviving more than 180 days was analyzed. EBVd was monitored in whole blood within the first 6 months using a real-time polymerase chain reaction assay. Using a Cox proportional hazards model, duration and magnitude of EBVd were assessed as potential surrogate markers for the occurrence of late adverse events (>6 months): graft dysfunction, graft loss, death, and immunosuppression-related adverse events (IRAE), defined by the occurrence of solid organ tumor and opportunistic and severe infections | ||
520 | |a RESULTS: A median of 10 blood samples per patient was screened. A total of 68 (84%) patients had detectable EBVd. Persistent EBVd (>30 days) was found in 40 (49.4%) and high EBVd (>1500 copies/mL) in 35 (43.3%). Multivariate analyses showed that persistent EVBd and high EBVd levels were independently related to the development of IRAE (hazard ratio, 2.95 and 4.32, respectively), whereas no significant associations were observed with late graft dysfunction or graft loss | ||
520 | |a CONCLUSIONS: Persistent and high levels of EBVd within the first 6 months after SOT are surrogate markers of increased risk of IRAE | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a Biomarkers |2 NLM | |
650 | 7 | |a DNA, Viral |2 NLM | |
700 | 1 | |a De Dios, Begoña |e verfasserin |4 aut | |
700 | 1 | |a Navarro, David |e verfasserin |4 aut | |
700 | 1 | |a García-Reyne, Ana |e verfasserin |4 aut | |
700 | 1 | |a Lumbreras, Carlos |e verfasserin |4 aut | |
700 | 1 | |a Bravo, Dayana |e verfasserin |4 aut | |
700 | 1 | |a Costa, Elisa |e verfasserin |4 aut | |
700 | 1 | |a Morales, Jose Maria |e verfasserin |4 aut | |
700 | 1 | |a Andres, Amado |e verfasserin |4 aut | |
700 | 1 | |a Jiménez-Romero, Carlos |e verfasserin |4 aut | |
700 | 1 | |a Delgado, Juan |e verfasserin |4 aut | |
700 | 1 | |a Fernández-Ruiz, Mario |e verfasserin |4 aut | |
700 | 1 | |a López-Medrano, Francisco |e verfasserin |4 aut | |
700 | 1 | |a Aguado, Jose M |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Transplantation |d 1963 |g 95(2013), 5 vom: 15. März, Seite 688-93 |w (DE-627)NLM000023787 |x 1534-6080 |7 nnns |
773 | 1 | 8 | |g volume:95 |g year:2013 |g number:5 |g day:15 |g month:03 |g pages:688-93 |
856 | 4 | 0 | |u http://dx.doi.org/10.1097/TP.0b013e31827a4bd6 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 95 |j 2013 |e 5 |b 15 |c 03 |h 688-93 |